In the Spotlight...
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer
Biodegradable targeted polymeric mRNA nanoparticles enable in vivo CD19 CAR T cell generation and lead to B cell depletion
Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer
Previous Digests
The surprising effect of TOX in CD4+ T cells
March 18, 2026
In settings of chronic antigen stimulation, such as chronic infection and cancer, expression of the transcription factor TOX in CD8+ T cells has been associated with cell persistence and survival, but also with exhaustion, dysfunction, and poor prognosis. As...
Neoantigen vaccination boosts long-lasting T cell responses in TNBC
March 11, 2026
Triple-negative breast cancer (TNBC) is characterized by DNA repair deficiency, genomic instability, and an immunogenic tumor microenvironment, suggesting it might serve as a candidate for individualized vaccination targeting somatic tumor mutation-associated neoantigens. Sahin, Schmidt, et al. recently published the...
AACR IO 2026
March 4, 2026
The ACIR team attended the AACR IO meeting held on February 18-21, 2026 in Los Angeles, CA, USA. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. T cellsPhilip...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
